NLS Pharmaceutics

31/10/2025

We’re excited to share that NLS Pharmaceutics and Kadimastem LTD have successfully merged to form NewCelX Ltd. (Nasdaq: NCEL)!
This merger brings together cell therapy and expertise to develop for , , and other serious — advancing hope for worldwide. 🌍

See link to our press release below in the comment!

30/10/2025

🚀 Big news from NLS Pharmaceutics!
Together with Aexon Labs, we’re expanding our DOXA platform with the innovative AEX-6xx series — designed to enhance cognition, arousal, and neuroprotection in neurodegenerative and metabolic disorders.
This exciting step marks another milestone in our commitment to science-driven innovation and patient-focused progress.

NLS Pharmaceutics Ltd. (Nasdaq: NLSP)(Nasdaq: NLSPW) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system and neurodegenerative disorders, and Aexon Labs, a biotechnology company advancing next-generation central nervous system ("CNS") therapeutics, today annou...

29/10/2025

We’re proud to share that the BIRD Foundation will continue supporting the ITOL-102 Diabetes cell-therapy program — developed with iTolerance Inc. — under our new merged company, NewCelX Ltd. 💙

Together, we remain focused on developing transformative therapies for patients living with Type 1 Diabetes.

NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS" or the "Company"), a biopharmaceutical company focused on developing innovative therapies for central nervous system and neurodegenerative disorders, and Kadimastem Ltd. (TASE: KDST) ("Kadimastem"), a clinical-stage cell therapy company developing treatme...

27/10/2025

The future of medicine is collaboration! 💫
Kadimastem LTD (Soon to be merged NewCelX) has announced a strategic partnership with TargetGene Biotechnologies to develop next-generation gene-edited cell therapies.
This partnership is a testament to our shared vision for safer, more effective, and life-changing therapies for patients around the world. 🌍

More info ➡️ https://finance.yahoo.com/news/nls-pharmaceutics-kadimastem-announce-strategic-110000693.html

NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system and neurodegenerative disorders and Kadimastem Ltd. (TASE: KDST) ("Kadimastem"), a clinical-stage biotechnology company developing breakthrough cell therapy solutions for...

23/10/2025

💥 Exciting news! Nasdaq has approved the merger of NLS Pharmaceutics and Kadimastem LTD — closing October 30, 2025!
The new company, NewCelX Ltd., will be listed on Nasdaq under the ticker “NCEL.”

This merger combines NLS’s CNS expertise with Kadimastem’s leadership in cell therapy to create a stronger, more diverse biotech company — dedicated to bringing life-changing treatments to patients.

🌍 Thank you to our shareholders, team, and partners for supporting this major milestone!
https://finance.yahoo.com/news/nls-kadimastem-announce-receipt-nasdaq-100000259.html

NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (Nasdaq: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system ("CNS") disorders, and Kadimastem Ltd. (TASE: KDST) ("Kadimastem"), an advanced clinical-stage cell therapy company developing treatments...

30/09/2025

Big news! 🎉 At yesterday’s Extraordinary General Meeting, NLS shareholders voted in favor of our merger with Kadimastem LTD. This approval clears one of the final steps before launching NewCelX Ltd. on Nasdaq.

NewCelX will bring together Kadimastem’s innovative cell therapy programs and NLS’s CNS drug expertise, creating a company with the power to tackle some of the toughest health challenges — from ALS to diabetes and beyond. 💡💊

Thank you to our shareholders for their strong support as we move into this exciting new chapter!
https://finance.yahoo.com/news/nls-pharmaceutics-shareholders-approve-merger-110000163.html

10/09/2025

📢 NLS Pharmaceutics and Kadimastem Ltd. Reach U.S. Regulatory Milestone Toward Merger!
We are excited to share that the U.S. Securities and Exchange Commission has declared effective our Form F-4 registration statement.

Together, the planned merged company — NewCelX Ltd. will combine NLS’s CNS-focused small-molecule therapies with Kadimastem LTD’s advanced cell therapy programs for and diseases.

🌍 Pipeline Highlights:
• AstroRx® Phase 2a trial preparations underway in the U.S.
• Continued advancement of IsletRx for diabetes following a successful Pre-IND FDA meeting
• Expanded pipeline bringing together cell therapy & small-molecule innovation

💬 Alex Zwyer, CEO of NLS:
“The SEC clearance of our F-4 filing marks the final step on the U.S. federal regulatory path toward closing our merger with Kadimastem. This combination is a transformational opportunity to build a next-generation biotech with a diversified pipeline and global reach.”

https://finance.yahoo.com/news/kadimastem-nls-pharmaceutics-announce-effectiveness-100000890.html

NLS Pharmaceutics Ltd. (Nasdaq: NLSP)(Nasdaq: NLSPW) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system ("CNS") disorders, and Kadimastem Ltd. (TASE: KDST) ("Kadimastem"), an advanced clinical-stage cell therapy company progressing treatments for neurodegener...

04/09/2025

Big news from our merger partner Kadimastem LTD:
A Hong Kong patent has been granted for its cell selection and enrichment technology, central to IsletRx, a potential curative therapy for insulin-dependent .

This patent complements earlier grants in the U.S., Europe, and India, reinforcing the strength of Kadimastem’s IP portfolio. Hong Kong also represents a significant diabetes market and an important gateway into Mainland China’s Greater Bay Area, supporting and ahead.

https://finance.yahoo.com/news/nls-pharmaceutics-kadimastem-announce-hong-110000802.html

17/07/2025

Major updates from NLS Pharmaceutics!

We're excited to announce that the BIRD Foundation has approved additional funding for iTOL-102, an innovative therapy being co-developed by Kadimastem LTD and iTolerance. iTOL-102 aims to cure Type 1 without requiring life-long immune suppression — a major step forward in diabetes care.

This comes on the heels of a successful Pre-IND meeting with the U.S. U.S. Food and Drug Administration, and the teams are now preparing for clinical trials.

But that's not all — our very own Prof Eric Konofal has been shortlisted for the prestigious Prix Galien France 2025, often called the Nobel Prize of pharma, for his pioneering research in narcolepsy. His work on the AEX series of orexin receptor agonists represents a transformative new approach to treating this debilitating condition.

From diabetes to neurodegeneration and narcolepsy — we are committed to delivering real breakthroughs to patients in need.

https://finance.yahoo.com/news/nls-pharmaceutics-highlights-continued-progress-110000400.html

30/06/2025

Exciting news: We’ve completed the final $1M closing of our $3M equity financing announced in March. This funding supports our upcoming merger with Kadimastem and sets the stage for clinical progress in ALS and diabetes.
We thank our investors and partners for their continued trust.
Kadimastem LTD
Full story here:

NLS Pharmaceutics Ltd. (NASDAQ: NLSP) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, today announced that it has completed the second and final $1 million closing of its previously disclosed $3 mi...

16/06/2025

NLS Pharmaceutics CEO Issues Letter to Shareholders: We’re proud to share major progress at NLS Pharmaceutics. Since late 2024, we’ve raised over $6 million, eliminated all outstanding debt, and delivered promising new preclinical data in our CNS and addiction platforms.

With our merger with Kadimastem LTD advancing, we’re preparing to launch Phase IIa and Phase I clinical trials in and Type 1 diabetes.
These achievements reflect our strengthened financial position and commitment to breakthrough science.

📄 Read more: https://finance.yahoo.com/news/nls-pharmaceutics-ceo-issues-letter-110000283.html

21/05/2025

NLS will be at the upcoming American Society of Clinical Psychopharmacology 2025 Annual Meeting, we'll be presenting preclinical data on the dual action of Mazindol ER in reducing both the rewarding effects of fentanyl and the severity of withdrawal symptoms in validated animal models.

👉 These findings support Mazindol's potential as a non-opioid therapeutic for opioid dependence.

Join us at our poster session on May 29 in Scottsdale, Arizona.

Learn more: https://finance.yahoo.com/news/nls-pharmaceutics-present-data-dual-113000452.html?guccounter=1

🔬 Study conducted in collaboration with Key-Obs SAS and leading EU institutions

Alex Zwyer Eric Konofal